Switching MS drugs for wearing-off symptoms
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests whether switching from ocrelizumab to a similar drug, ublituximab, can help people with MS who experience 'wearing-off' symptoms before their next infusion. It may offer a new option to keep symptoms more stable between doses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a relapsing form of MS.
- You are between 18 and 65 years old.
- You have been taking ocrelizumab (Ocrevus) for at least one year.
- You notice your MS symptoms get worse before your next infusion (wearing-off).
- You have not taken other B-cell therapies like rituximab, ofatumumab, or ublituximab before.
- You do not have a current serious infection, low blood cell counts, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what happens to infection-fighting antibody levels when people with relapsing multiple sclerosis switch from ocrelizumab to ofatumumab. It may help doctors understand if switching is a good option for people whose antibody levels are low.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This study tests ublituximab (Briumvi), a treatment given as an infusion, for people recently diagnosed with relapsing MS. The goal is to see if starting this treatment early helps control MS better.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.